{"protocolSection":{"identificationModule":{"nctId":"NCT01101334","orgStudyIdInfo":{"id":"CS7017-A-U204"},"organization":{"fullName":"Daiichi Sankyo","class":"INDUSTRY"},"briefTitle":"Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer","officialTitle":"Phase 2 Study of CS-7017 and Erlotinib in Subjects With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy"},"statusModule":{"statusVerifiedDate":"2020-06","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-03"},"primaryCompletionDateStruct":{"date":"2013-04","type":"ACTUAL"},"completionDateStruct":{"date":"2013-04","type":"ACTUAL"},"studyFirstSubmitDate":"2010-04-07","studyFirstSubmitQcDate":"2010-04-08","studyFirstPostDateStruct":{"date":"2010-04-09","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-05-19","resultsFirstSubmitQcDate":"2020-06-12","resultsFirstPostDateStruct":{"date":"2020-06-16","type":"ACTUAL"},"dispFirstSubmitDate":"2014-05-07","dispFirstSubmitQcDate":"2014-05-07","dispFirstPostDateStruct":{"date":"2014-05-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2020-06-12","lastUpdatePostDateStruct":{"date":"2020-06-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Daiichi Sankyo","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This is a Phase 2 and open-label (subject will know the treatment he or she is receiving) study. The subject will receive either Erlotinib alone or Erlotinib + CS-7017 in this study.\n\nThe study will determine what effect adding CS-7017 to Erlotinib has on safety and length of survival in subjects with advanced non-small cell lung cancer who failed the first treatment."},"conditionsModule":{"conditions":["Advanced Non-small Cell Lung Cancer (NSCLC)"],"keywords":["NSCLC"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":90,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"CS-7017 plus erlotinib","type":"EXPERIMENTAL","interventionNames":["Drug: CS-7017","Drug: erlotinib"]},{"label":"erlotinib","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: erlotinib"]}],"interventions":[{"type":"DRUG","name":"CS-7017","description":"CS-7017, Two 0.25mg Tablets administered twice daily","armGroupLabels":["CS-7017 plus erlotinib"]},{"type":"DRUG","name":"erlotinib","description":"Erlotinib; One 150mg tablet administered once daily","armGroupLabels":["CS-7017 plus erlotinib","erlotinib"],"otherNames":["Tarceva"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Summary of Analysis of Progression-Free Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy","description":"Progression-free survival (PFS) was defined as the time from randomization date of the first objective documentation of disease progression or death resulting from any cause, whichever comes first.","timeFrame":"Baseline to disease progression or death, up to approximately 2.5 years"}],"secondaryOutcomes":[{"measure":"Analysis of Overall Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy","description":"Overall survival (OS) was defined as the time from randomization until death from any cause.","timeFrame":"Baseline to death, up to approximately 2.5 years"},{"measure":"Overall Response Rate Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy","description":"The overall response rate (ORR) was defined as the proportion of participants who achieved best overall response of complete response (CR) or partial response (PR); ORR = CR + PR. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, CR was defined as the disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.","timeFrame":"Baseline to disease progression or death, up to approximately 2.5 years"},{"measure":"Summary of Treatment-Emergent Adverse Events (TEAEs) Occurring in ≥10% of Participants Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy","description":"A treatment-emergent adverse event (TEAE) was defined as an adverse event that had an onset date on or after the first dose of CS-7017 or erlotinib up to and including 30 days after the last dose of any study drug, or worsened in severity after the first dose of CS-7017 or erlotinib relative to the pre-treatment state.","timeFrame":"Baseline to 30 days after last dose, up to approximately 2.5 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed stage IIIB or IV NSCLC.\n* Recurrent disease (either no response to treatment or subsequent relapse after an objective response) that has progressed after first line therapy.\n* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 criteria.\n* ≥ 18 years of age.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n* Adequate organ and bone marrow function.\n* Resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0 grade ≤ 1.\n* Agreement to use effective contraception while on treatment and for at least 3 months after end of treatment.\n\nExclusion Criteria:\n\n* Treatment with anticancer therapy within 3 weeks before study treatment.\n* Therapeutic or palliative radiation therapy within 2 weeks or major surgery within 4 weeks before study treatment (except for radiotherapy for brain metastases).\n* Administration of other thiazolidinediones (TZDs) within 4 weeks before study treatment.\n* Current need for concomitant use of other TZDs during the study.\n* Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection at time of screening.\n* History of any of the following conditions within 6 months before initiating study treatment: diabetes mellitus requiring treatment with insulin or TZD agents; myocardial infarction with significant impairment of cardiac function; severe/unstable angina pectoris; coronary/peripheral artery bypass graft; New York Heart Association (NYHA) class III or IV congestive heart failure; malabsorption syndrome, chronic diarrhea (lasting \\> 4 weeks), inflammatory bowel disease, or partial bowel obstruction.\n* Pericardial or pleural effusion (eg, requiring drainage) or pericardial involvement with the tumor. Participants with minimal pleural effusion may be eligible upon request by Investigator and approval by Sponsor.\n* Pregnant or breast feeding.\n* Prior treatment with epidermal growth factor receptor (EGFR) inhibitors.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Global Clinical Leader","affiliation":"Daiichi Sankyo","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"DHHA","city":"Denver","state":"Colorado","zip":"80204","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Gabrail Cancer Center","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"Providence Regional Medical Center Everett","city":"Everett","state":"Washington","zip":"98201","country":"United States","geoPoint":{"lat":47.97898,"lon":-122.20208}},{"facility":"Zentrum fur Pneumologie und Thoraxchirurgie","city":"Gauting","zip":"D-82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"facility":"King George Hospital","city":"Visakhapatnam","state":"Andhra Pradesh","zip":"530002","country":"India","geoPoint":{"lat":17.68009,"lon":83.20161}},{"facility":"Vedanta Institute of Medical Sciences","city":"Ahmedabad","state":"Gujarat","zip":"380009","country":"India","geoPoint":{"lat":23.02579,"lon":72.58727}},{"facility":"Kodlikeri Memorial Hospital","city":"Aurangabad","state":"Maharashtra","zip":"431001","country":"India","geoPoint":{"lat":19.87757,"lon":75.34226}},{"facility":"Tata Memorial Hospital","city":"Mumbai","state":"Maharashtra","zip":"400012","country":"India","geoPoint":{"lat":19.07283,"lon":72.88261}},{"facility":"Noble Hospital","city":"Pune","state":"Maharashtra","zip":"411 013","country":"India","geoPoint":{"lat":18.51957,"lon":73.85535}},{"facility":"Apollo Speciality Hospital","city":"Chennai","state":"Tamil Nadu","zip":"600 035","country":"India","geoPoint":{"lat":13.08784,"lon":80.27847}},{"facility":"Meenakshi Mission Hospital","city":"Madurai","state":"Tamil Nadu","zip":"625107","country":"India","geoPoint":{"lat":9.919,"lon":78.11953}},{"facility":"Orchid Nursing Home","city":"Kolkata","state":"West Bengal","zip":"700 054","country":"India","geoPoint":{"lat":22.56263,"lon":88.36304}},{"facility":"St. Vincent's Hospital","city":"Gyeonggi-do","zip":"442-723","country":"South Korea","geoPoint":{"lat":37.58944,"lon":126.76917}},{"facility":"Hwasun Hospital","city":"Jeonnam","zip":"519-763","country":"South Korea"},{"facility":"Severance Hospital","city":"Seoul","zip":"120-752","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","zip":"135-710","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center","city":"Seoul","zip":"138-736","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.","accessCriteria":"Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.","url":"https://vivli.org/ourmember/daiichi-sankyo/"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"A total of 90 participants who met all inclusion and no exclusion criteria were randomized to treatment; 89 participants received treatment.","groups":[{"id":"FG000","title":"CS-7017 Plus Erlotinib","description":"Participants who received two 0.25 mg CS-7017 tablets administered twice daily and one 150 mg erlotinib tablet administered once daily."},{"id":"FG001","title":"Erlotinib","description":"Participants who received one 150 mg erlotinib tablet administered once daily."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"45"}]},{"type":"Received Study Treatment","achievements":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"45"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"45"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Withdrawal by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Progressive Disease","reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"35"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Baseline characteristics are reported for all participants who received treatment.","groups":[{"id":"BG000","title":"CS-7017 Plus Erlotinib","description":"Participants who received two 0.25 mg CS-7017 tablets administered twice daily and one 150 mg erlotinib tablet administered once daily."},{"id":"BG001","title":"Erlotinib","description":"Participants who received one 150 mg erlotinib tablet administered once daily."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"89"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"64"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"25"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.6","spread":"10.36"},{"groupId":"BG001","value":"61.4","spread":"11.34"},{"groupId":"BG002","value":"60.5","spread":"10.85"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"31"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"58"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Summary of Analysis of Progression-Free Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy","description":"Progression-free survival (PFS) was defined as the time from randomization date of the first objective documentation of disease progression or death resulting from any cause, whichever comes first.","populationDescription":"PFS was assessed in the Full Analysis Set.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to disease progression or death, up to approximately 2.5 years","groups":[{"id":"OG000","title":"CS-7017 Plus Erlotinib","description":"Participants who received two 0.25 mg CS-7017 tablets administered twice daily and one 150 mg erlotinib tablet administered once daily."},{"id":"OG001","title":"Erlotinib","description":"Participants who received one 150 mg erlotinib tablet administered once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","lowerLimit":"2.7","upperLimit":"6.7"},{"groupId":"OG001","value":"3.0","lowerLimit":"2.2","upperLimit":"5.3"}]}]}]},{"type":"SECONDARY","title":"Analysis of Overall Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy","description":"Overall survival (OS) was defined as the time from randomization until death from any cause.","populationDescription":"OS was assessed in the Full Analysis Set.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to death, up to approximately 2.5 years","groups":[{"id":"OG000","title":"CS-7017 Plus Erlotinib","description":"Participants who received two 0.25 mg CS-7017 tablets administered twice daily and one 150 mg erlotinib tablet administered once daily."},{"id":"OG001","title":"Erlotinib","description":"Participants who received one 150 mg erlotinib tablet administered once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"3.8","upperLimit":"12.0"},{"groupId":"OG001","value":"11.4","lowerLimit":"9.7","upperLimit":"15.0"}]}]}]},{"type":"SECONDARY","title":"Overall Response Rate Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy","description":"The overall response rate (ORR) was defined as the proportion of participants who achieved best overall response of complete response (CR) or partial response (PR); ORR = CR + PR. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, CR was defined as the disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.","populationDescription":"ORR was assessed in the Full Analysis Set.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline to disease progression or death, up to approximately 2.5 years","groups":[{"id":"OG000","title":"CS-7017 Plus Erlotinib","description":"Participants who received two 0.25 mg CS-7017 tablets administered twice daily and one 150 mg erlotinib tablet administered once daily."},{"id":"OG001","title":"Erlotinib","description":"Participants who received one 150 mg erlotinib tablet administered once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"45"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}]}]},{"type":"SECONDARY","title":"Summary of Treatment-Emergent Adverse Events (TEAEs) Occurring in ≥10% of Participants Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy","description":"A treatment-emergent adverse event (TEAE) was defined as an adverse event that had an onset date on or after the first dose of CS-7017 or erlotinib up to and including 30 days after the last dose of any study drug, or worsened in severity after the first dose of CS-7017 or erlotinib relative to the pre-treatment state.","populationDescription":"TEAEs were assessed in the Safety Analysis Set.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Baseline to 30 days after last dose, up to approximately 2.5 years","groups":[{"id":"OG000","title":"CS-7017 Plus Erlotinib","description":"Participants who received two 0.25 mg CS-7017 tablets administered twice daily and one 150 mg erlotinib tablet administered once daily."},{"id":"OG001","title":"Erlotinib","description":"Participants who received one 150 mg erlotinib tablet administered once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"45"}]}],"classes":[{"title":"Any TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"43"}]}]},{"title":"Blood and Lymphatic System Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"4"}]}]},{"title":"Anaemia","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"3"}]}]},{"title":"Cardiac Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"}]}]},{"title":"Eye Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"}]}]},{"title":"Gastrointestinal Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"25"}]}]},{"title":"Constipation","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"}]}]},{"title":"Diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"19"}]}]},{"title":"Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"}]}]},{"title":"Stomatitis","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}]}]},{"title":"General Disorders & Administration Site Conditions","categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"19"}]}]},{"title":"Asthenia","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}]},{"title":"Disease progression","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}]},{"title":"Face edema","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"0"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"}]}]},{"title":"Noncardiac chest pain","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Edema peripheral","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"1"}]}]},{"title":"Pyrexia","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}]}]},{"title":"Infections and Infestations","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"16"}]}]},{"title":"Investigations","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"12"}]}]},{"title":"Weight increased","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}]}]},{"title":"Metabolism and Nutrition Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"15"}]}]},{"title":"Decreased appetite","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"}]}]},{"title":"Hypokalemia","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}]}]},{"title":"Musculoskeletal and Connective Tissue Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"10"}]}]},{"title":"Pain in extremity","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"}]}]},{"title":"Nervous System Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}]}]},{"title":"Dizziness","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]},{"title":"Psychiatric Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]}]},{"title":"Respiratory, Thoracic, and Mediastinal Disoders","categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"17"}]}]},{"title":"Cough","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"}]}]},{"title":"Pleural effusion","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"0"}]}]},{"title":"Skin and Subcutaneous Tissue Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"30"}]}]},{"title":"Alopecia","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}]}]},{"title":"Dermatitis acneiform","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"}]}]},{"title":"Dry skin","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"}]}]},{"title":"Pruritus","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}]},{"title":"Rash","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"15"}]}]},{"title":"Swelling face","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]},{"title":"Vascular Disorders","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Treatment-emergent adverse event (TEAE) data were collected from time of signing the informed consent form to the end of study assessment and follow-up period (30 days after last dose of study drug), up to approximately 2.5 years.","description":"A TEAE was defined as an adverse event that had an onset date on or after the first dose of CS-7017 or erlotinib up to and including 30 days after the last dose of any study drug, or worsened in severity after the first dose of CS-7017 or erlotinib relative to the pre-treatment state. All-cause mortality includes all deaths caused by TEAEs.","eventGroups":[{"id":"EG000","title":"CS-7017 Plus Erlotinib","description":"Participants who received two 0.25 mg CS-7017 tablets administered twice daily and one 150 mg erlotinib tablet administered once daily.","deathsNumAffected":15,"deathsNumAtRisk":44,"seriousNumAffected":24,"seriousNumAtRisk":44,"otherNumAffected":44,"otherNumAtRisk":44},{"id":"EG001","title":"Erlotinib","description":"Participants who received one 150 mg erlotinib tablet administered once daily.","deathsNumAffected":7,"deathsNumAtRisk":45,"seriousNumAffected":16,"seriousNumAtRisk":45,"otherNumAffected":43,"otherNumAtRisk":45}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":45}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":4,"numAtRisk":45}]},{"term":"Hematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":45}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":2,"numAtRisk":45}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":45}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":44},{"groupId":"EG001","numAffected":5,"numAtRisk":45}]},{"term":"Multi-organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Edema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":45}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":2,"numAtRisk":45}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Metastatic pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Paraneoplastic syndrome","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":45}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Femoral arterial stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":45}]},{"term":"Macroangiopathy","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":45}]},{"term":"Pelvic venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":45}]},{"term":"Vascular stenosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":45}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":44},{"groupId":"EG001","numAffected":3,"numAtRisk":45}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":44},{"groupId":"EG001","numAffected":1,"numAtRisk":45}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":44},{"groupId":"EG001","numAffected":5,"numAtRisk":45}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":44},{"groupId":"EG001","numAffected":5,"numAtRisk":45}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":44},{"groupId":"EG001","numAffected":0,"numAtRisk":45}]},{"term":"Any Blood and Lymphatic System Disorders","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":44},{"groupId":"EG001","numAffected":4,"numAtRisk":45}]},{"term":"Any Cardiac Disorders","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":44},{"groupId":"EG001","numAffected":2,"numAtRisk":45}]},{"term":"Any General Disorders & Administration Site Conditions","organSystem":"General disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":44},{"groupId":"EG001","numAffected":19,"numAtRisk":45}]},{"term":"Any Investigations","organSystem":"Investigations","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":44},{"groupId":"EG001","numAffected":12,"numAtRisk":45}]},{"term":"Any Neoplasms Benign, Malignant, and Unspecified (Including Cysts and Polyps)","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":44},{"groupId":"EG001","numAffected":2,"numAtRisk":45}]},{"term":"Any Respiratory, Thoracic, and Mediastinal Disorders","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":44},{"groupId":"EG001","numAffected":17,"numAtRisk":45}]},{"term":"Any Skin and Subcutaneous Tissue Conditions","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (13.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":44},{"groupId":"EG001","numAffected":30,"numAtRisk":45}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Contact for Clinical Trial Information","organization":"Daiichi Sankyo","email":"CTRinfo@dsi.com","phone":"908-992-6400"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"interventionBrowseModule":{"meshes":[{"id":"C510342","term":"efatutazone"},{"id":"D000069347","term":"Erlotinib Hydrochloride"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}